5,7,8-trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2328-2340

  Koini, Eftychia N ^a   Papazafiri, Panagiota ^b   Vassilopoulos, Athanasios ^c,e   Koufaki, Maria ^a   Horváth, Zoltán ^d   Koncz, István ^c   Virág, László ^c   Papp, Gy J ^c,d   Varró, Andràs ^c,d   Calogeropoulou, Theodora ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF SZEGED   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 CHLORO 2,2,5,7,8 PENTAMETHYL 2,3 DIHYDRO 1,4 BENZOXAZIN 4 YL) 2 DIETHYLAMINOETHANONE; 1 (6 CHLORO 5,7,8 TRIMETHYL 2 PHENYL 2,3 DIHYDRO 1,4 BENZOXAZIN 4 YL) 2 DIETHYLAMINOETHANONE; 1 (6 CHLORO 5,7,8 TRIMETHYL 2,3 DIHYDRO 1,4 BENZOXAZIN 4 YL) 2 DIETHYLAMINOETHANONE; 1 (6 METHOXY 5,7,8 TRIMETHYL 2 PHENYL 2,3 DIHYDRO 1,4 BENZOXAZIN 4 YL) 2 DIETHYLAMINOETHANONE; 2 DIETHYLAMINO 1 (2,2,5,7,8 PENTAMETHYL 2,3 DIHYDRO 1,4 BENZOXAZIN 4 YL)ETHANONE; 2 DIETHYLAMINO 1 (5,7,8 TRIMETHYL 2 PHENYL 2,3 DIHYDRO 1,4 BENZOXAZIN 4 YL)ETHANONE; 2 DIETHYLAMINO 1 (5,7,8 TRIMETHYL 2 PHENYL 2,3 DIHYDROBENZ[1,4]OXAZIN 4 YL)ETHANONE; 4 (2 DIETHYLAMINOACETYL) 2,5,7,8 TETRAMETHYL 3,4 DIHYDRO 2H BENZ[1,4]OXAZINE 2 CARBOXYLIC ACID ETHYL ESTER; 5,7,8 TRIMETHYL 1,4 BENZOXAZINE DERIVATIVE; 5,7,8 TRIMETHYLBENZOPYRAN DERIVATIVE; 6 HYDROXY 5,7,8 TRIMETHYLBENZOPYRAN DERIVATIVE; ANTIARRHYTHMIC AGENT; BENZOPYRAN DERIVATIVE; BENZOXAZINE DERIVATIVE; DIETHYLAMINO 1 (5,7,8 TRIMETHYL 2,3 DIHYDRO 1,4 BENZOXAZIN 4 YL)ETHANONE; LIDOCAINE; MALONALDEHYDE; N (3,4 DIHYDRO 2 PHENYL 6 HYDROXY 5,7,8 TRIMETHYL 2H 1 BENZOPYRAN 4 YL)(DIETHYLAMINO)ACETAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; EXTRASYSTOLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART PROTECTION; MALE; MICROELECTRODE; NONHUMAN; PHARMACOPHORE; RABBIT; RAT; REPERFUSION INJURY; SCORING SYSTEM; TISSUE LEVEL;

ACTION POTENTIALS; AMIDES; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIOXIDANTS; BENZOPYRANS; BENZOXAZINES; FEMALE; HEART; LIPID PEROXIDATION; MALE; MYOCARDIAL REPERFUSION INJURY; PAPILLARY MUSCLES; RABBITS; RATS; RATS, WISTAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65249088365     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801228h     Document Type: Article

References (68)

1. Janse, M. J.; Wit, A. L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol. Rev. 1989, 69, 1049-1169.
2. (a) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction. N. Engl. J. Med. 1989, 321, 406-412;
3. (b) The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N. Engl. J. Med., 1992, 327, 227-233.
4. Zareba, W. Implantable cardioverter defibrillator therapy in postinfarction patients. Curr. Opin. Cardiol. 2004, 19, 619-624.
5. (4)
6. (a) Piper, H. M.; Garcia-Dorado, D.; Ovize, M. A. fresh look at reperfusion injury. Cardiovasc. Res. 1998, 38, 291-300.
7. (b) An-dreadou, I.; Iliodromitis, E. K.; Koufaki, M.; Farmakis, D.; Tsotinis, A.; Kremastinos, D. Th. Alternative Pharmacological Interventions that Limit Myocardial Infarction. Curr. Med. Chem. 2008, 15, 3204- 3213.
8. Ambrosio, G.; Tritto, I. Reperfusion injury: experimental evidence and clinical implications. Am. Heart J. 1999, 138, S69-S75.
9. (a) Park, J. L.; Lucchesi, B. R. Mechanisms of myocardial reperfusion injury. Ann. Thorac. Surg. 1999, 68, 1905-1912.
10. (b) Yellon, D. M.; Hausenloy, D. J. Myocardial Reperfusion Injury. N. Engl. J. Med. 2007, 357, 1121-1135.
11. (a) Piper, H. M.; Meuter, K.; Schäfer, C. Cellular mechanisms of ischemia-reperfusion injury. Ann. Thorac. Surg. 2003, 75, S644-S648.
12. (b) Woodcock, E. A. Roles of alpha1A- and alpha1B-adrenoceptors in heart: insights from studies of genetically modified mice. Clin. Exp. Pharmacol. Physio. 2007, 34, 884-888.
13. 3) regulates phospholipase Cβ1 expression in cardiomyocytes. J. Mol. Cell. Cardiol. 2008, 45, 679-684.
14. (a) Wang, Q. D.; Pernow, J.; Sjoquist, P. O.; Ryden, L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc. Res. 2002, 55, 25-37.
15. (b) Grover, G. J.; Garlid, K. D. ATP-Sensitive Potassium Channels: A Review of their Cardioprotective Pharmacology. J. Mol. Cell. Cardiol 2000, 32, 677-695.
16. Parrat, J. R. Inhibitors of the slow calcium current and early ventricular arrhythmias In: Parratt, J. R., Ed.; Early Arrhythmias Resulting from Myocardial Ischemia; Macmillan: London, 1982, 329-346.
17. He, Z. S.; Komori, S.; Tamura, K.; Hashimoto, K. Inhibitory effect of moricizine on reperfusion induced tachyarrhythmias in rats. A comparison study with disopyramide and mexiletine. Jpn. Circ. J. 1992, 56, 861-865.
18. Corr, P. B.; Pogwizd, S. M. Mechanisms contributing to arrhythmo-genesis during early myocardial ischemia, subsequent reperfusion, and chronic infarction. Angiology 1988, 39, 684-699.
19. Komori, S.; Sano, S.; Li, B. H; Matsumara, K.; Naitoh, A.; Mochizuki, S.; Ishihara, T.; Watanabe, A.; Umetani, K.; Iiiri, H.; Hashimoto, K.; Tamura, K. Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and dispyramide. Heart Vessel 1995, 10, 7-11.
20. Butwell, N. B.; Ramasamy, R.; Lazar, I.; Sherry, A. D.; Malloy, C. R. Effect of lidocaine on contracture, intracellular sodium and pH in ischemic rat hearts. Am. J. Physiol 1993, 264, H1884-H1889.
21. + exchange. Circ. Res. 1989, 65, 1045-1056.
22. Pike, M. M.; Kitakaze, M.; Chacko, V. P.; Marban, E. Lidocaine prevents the increase in myocardial free calcium during ischemia and reperfusion: an antiarrhythmic mechanism. Circulation 1987, 76, IV-16.
23. Saint, D. A. The cardiac persistent sodium current: an appealing therapeutic target? Br. J. Pharmacol. 2008, 153, 1133-1142.
24. Arakawa, J.; Hara, A.; Kokita, N. Lidocaine attenuates mechanical and metabolic derangements induced by palmitoyl-L-carnitine in the isolated perfused rat heart. Pharmacoloev 1997, 55, 259-268.
25. Das, D. K.; Misra, H. P. Lidocaine: a hydroxyl radical scavenger and singlet oxygen quencher. Mol. Cell. Biochem. 1992, 115, 179-185.
26. Josephson, I. R. Lidocaine blocks Na, Ca, and K currents of chick ventricular myocytes. J. Mol. Cell. Cardiol. 1988, 20, 593-604.
27. Sugiyama, K; Muteki, T. Local anesthetics depress the calcium current of rat sensory neurons in culture. Anesthesiology 1994, 80, 1369-1378.
28. Kojima, M.; Mura, M. Protective effect of lidocaine on the ischemic-reperfused rat heart: a phosphorus 31 nuclear magnetic resonance study. Basic Res. Cardiol. 1993, 28, 619-628.
29. Ohmura, T.; Muramatsu, I.; Kigoshi, S.; Noguchi, H.; Muraoka, R.; Komoriya, Y.; Hayashi, H. Novel cardioprotective effects of TYB-3823 on ischemic damage in the working hearts of rats: comparison with lidocaine. J. Pharmacol. Exp. Ther. 1990, 254, 696-701.
30. Vitola, J. V.; Forman, M. B.; Holsinger, J. P.; Atkinson, J. B.; Murray, J. J. Reduction of myocardial infarct size in rabbits and inhibition of activation of rabbit and human neutrophils by lidocaine. Am. Heart J. 1997, 133, 315-322.
31. Wendland, M. F.; Saeed, M.; Kondo, C; Derugin, N.; Higgins, C. B. Effect of lidocaine on acute regional myocardial ischemia and reperfusion in the cat. An in-vivo 31P magnetic resonance spectroscopy study. Invest. Radiol. 1993, 28, 619-628.
32. Hatori, N.; Roberts, R. L.; Tadokoro, H.; et al. Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. J. Cardiovasc. Phar-macol. 1991, 18, 581-588.
33. Lee, R.; Nitta, T.; Schmid, R. A.; Schuessler, R. B.; Harris, K. M.; Gay, W. A. Retrograde infusion of lidocaine or L-arginine before reperfusion reduces myocardial infarct size. Ann. Thorac. Surg. 1998, 65, 1353-1359.
34. Lesnefsky, E. J.; Van Benthuysen, K. M.; McMurtry, I. F.; Shikes, R. H.; Johnston, R. B.; Horwitz, L. D. Lidocaine reduces canine infarct size and decreases release of a lipid peroxidation product. J. CardioVasc. Pharmacol. 1989, 13, 895-901.
35. Koufaki, M.; Calogeropoulou, T.; Rekka, E.; Chryselis, M.; Papazafiri, P.; Gaitanaki, C; Makriyannis, A. Bifunctional Agents for Reperfusion Arrhythmias: Novel Hybrid Vitamin E/Class I Antiarrhythmics. Bioorg. Med. Chem. 2003, 11, 5209-5219.
36. Koufaki, M.; Kiziridi, C; Papazafiri, P.; Vassilopoulos, A.; Varró, A.; Nagy, Z.; Farkas, A.; Makriyannis, A. Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores. Bioorg. Med. Chem. 2006, 14, 6666-6678.
37. Zhang, W. H.; Chan, W. L.; Lin, Y. H.; Szeto, Y. S.; Lin, Y. C; Yeung, C. H. Synthesis of hydroxyflavanones from substituted acetophenones and benzaldehydes in the presence of silica gel, boric acid and piperidine. Heterocycles 1997, 45, 71-75.
38. Kano, S.; Tanaka, Y.; Sugino, E.; Hibino, S. Reduction of some functional groups with titanium (IV) chloride/sodium borohydride. Synthesis 1980, 695-697.
39. Phillips, G. B.; Morgan, T. K.; Nickish, K.; Lind, J. M.; Gomez, R. P.; Wohl, R. A.; Argentieri, T. M.; Sullivan, M. E. Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. J. Med. Chem. 1990, 33, 627-633.
40. Ouertani, M.; Girard, P.; Kagan, H. B. Selective Nitration of Phenols Catalyzed by Lanthanum (III) Nitrate. Tetrahedron Lett. 1982, 23, 4315-4318.
41. Ono, A.; Hiroi, M.; Shimazaki, K.; Reduction of aromatic nitrocompounds by the sodium borohydride-copper (I) chloride system.; Chem. Ind. 1984, 75.
42. Malen, C; Lacoste, J.-M.; Vilaine, J.-P.; Lenaers, A. Acylaminophenol compounds. U. S. Patent 5254590, 1993.
43. Mortensen, D. S.; Rodriguez, A. L.; Carlson, K. E.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Synthesis and biological evaluation of a novel series of furans: ligands selective for estrogen receptor alpha. J. Med. Chem. 2001, 44, 3838-3848.
44. Cava, M. P.; Leninsson, M. I. Thionation Reactions of Lawesson Reagents. Tetrahedron 1985, 41, 5061-5087.
45. Lepore, S. D.; He, Y. Use of Sonication for the Coupling of Sterically Hindered Substrates in the Phenolic Mitsunobu Reaction. J. Org. Chem. 2003, 68, 8261-8263.
46. Caron, S.; Vasquez, E. Efficient Synthesis of [6-Chloro-2- (4-chlo-robenzoyl) -1 H-indol-3-yl]-acetic Acid, a Novel COX-2 Inhibitor. J. Org. Chem. 2003, 68, 4104-4107.
47. Heisler, B. E.; Ferrier, G. Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion. J. Pharmacol. Exp. Ther. 1996, 279, 317-324.
48. Walker, M.; Curtis, M.; Hearse, D. The Lambeth Conventions: guidelines of the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiol. Res. 1988, 22, 447-455.
49. (a) Ceconi, C.; Cargnoni, A.; Pasini, E.; Condorelli, E.; Curello, S.; Ferrari, R. Evaluation of phospholipid peroxidation as malondialdehyde during myocardial ischemia and reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 1991, 260, H1057-H1061.
50. (b) Lefer, D. J.; Granger, N. Oxidative Stress and Cardiac Disease. Am. J. Med. 2000, 109, 315-323.
51. Draper, H. H.; Hardley, M. Malondialdehyde Determination as Index of Lipid Peroxidation. Methods Enzymol. 1990, 186, 283-293.
52. Lathrop, D. A.; Varró, A.; Nánási, P. P.; Bódi, I. I.; Takyi, E.; Pankucsi, C. Differences in the Effects of D- and DL-Sotalol on Isolated Human Ventricular Muscle: Electromechanical Activity after Beta-Adreno-receptor Stimulation. J. Cardiovasc. Pharmacol. Ther. 1996, 1, 65-74.
53. max of action potential upstroke in canine cardiac Purkinje fibers. J. Cardiovasc. Pharmacol. 1985, 7, 482-492.
54. (b) Varró, A.; Lathrop, D. A. Sotalol and mexiletine: combination of rate-dependent electrophysiological effects. J. Cardiovasc. Pharmacol. 1990, 16, 557-567.
55. (c) Mátyus, P.; Varga, I.; Rettegi, T.; Simay, A.; Kállay, N.; Károlyházy, L.; Kocsis, A.; Varró, A.; Pénzes, I.; Papp, J. G. Novel antiarrhythmic compounds with combined class IB and class III mode of action. Curr. Med. Chem. 2004, 11, 61-69.
56. Campbell, T. J.; Vaughan Williams, E. M. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc. Res. 1983, 17, 251-258.
57. Campbell, T. J. Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle and provide a theoretical basis for their subclassification. Cardiovasc. Res. 1983, 17, 344-352.
58. max. Br. J. Pharmacol. 1991, 103, 1568-1572.
59. Papp, J. G.; Németh, M.; Krassói, I. I.; Mester, L.; Hála, O.; Varró, A. Differential Electrophysiologic Effects of Chronically Administered Amiodarone on Canine Purkinje Fibers versus Ventricular Muscle. J. Cardiovasc. Pharmacol. Ther. 1996, 1, 287-296.
60. Gerebtzoff, G.; Li-Blatter, X.; Fischer, H.; Frentzel, A.; Seelig, A. Halogenation of Drugs Enhances Membrane Binding and Permeation. ChemBioChem 2004, 5, 676-684.
61. (a) Achari, B.; Mandal, S. B.; Dutta, P. K.; Chowdhurry, C. Perspectives on 1, 4-benzoxazines and their 2, 3-dihydro derivatives. Synlett., 2004, 2449-2467.
62. ATP Channel Openers. Curr. Top. Med. Chem. 2006, 6, 1049-1068.
63. Ilaš, J.; Anderluh, P.; Dolenc, M. S.; Kikelj, D. Recent advances in the synthesis of 2H-1, 4-benzoxazin-3- (4H) -ones and 3, 4-dihydro-2H-1, 4-benzoxazines. Tetrahedron 2005, 61, 7325-7348.
64. Rybczynski, P. J.; Zeck, R. E.; Dudash, J.; Combs, D. W.; Burris, T. P.; Yang, M.; Osborne, M. C.; Chen, X.; Demarest, K. T. Benzoxazinones as PPARα Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model. J. Med. Chem. 2004, 47, 196-209.
65. The corresponding compounds were detected by GC-MS but decomposed upon isolation.
66. (a) Pratt, C. M.; Camm, A. J.; Cooper, W.; Friedman, P. L.; MacNeil, D. J.; Moulton, K. M.; Pitt, B.; Schwartz, P. J.; Veltri, E. P.; Waldo, A. L. Mortality in the Survival With Oral D-sotalol (SWORD) trial: why did patients die? Am. J. Cardiol. 1998, 81, 869-876.
67. (b) Waldo, A. L.; Camm, A. J.; deRuyter, H.; Friedman, P. L.; MacNeil, D. J.; Pauls, J. F.; Pitt, B.; Pratt, C. M.; Schwartz, P. J.; Veltri, E. P. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators Survival With Oral D-Sotalol. Lancet 1996, 348, 7-12.
68. (c) Waldo, A. L.; Camm, A. J.; deRuyter, H.; Freidman, P. L.; MacNeil, D. J.; Pitt, B.; Pratt, C. M.; Rodda, B. E.; Schwartz, P. J. Survival with oral D-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am. J. Cardiol. 1995, 75, 1023-1027.